Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Net Cash Flow (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Net Cash Flow over the past 3 years, most recently at $18.5 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $18.5 million for Q4 2025, down 73.81% from a year ago — trailing twelve months through Dec 2025 was $110.2 million (up 49.21% YoY), and the annual figure for FY2025 was $110.2 million, up 49.21%.
  • Net Cash Flow for Q4 2025 was $18.5 million at Tonix Pharmaceuticals Holding, down from $65.1 million in the prior quarter.
  • Over the last five years, Net Cash Flow for TNXP hit a ceiling of $70.5 million in Q4 2024 and a floor of -$48.2 million in Q1 2023.
  • Median Net Cash Flow over the past 3 years was $7.5 million (2023), compared with a mean of $7.5 million.
  • Biggest five-year swings in Net Cash Flow: skyrocketed 293.03% in 2024 and later plummeted 120.42% in 2025.
  • Tonix Pharmaceuticals Holding's Net Cash Flow stood at $17.9 million in 2023, then skyrocketed by 293.03% to $70.5 million in 2024, then tumbled by 73.81% to $18.5 million in 2025.
  • The last three reported values for Net Cash Flow were $18.5 million (Q4 2025), $65.1 million (Q3 2025), and -$6.4 million (Q2 2025) per Business Quant data.